LISTEN TO ARTICLE 2:16 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email
Bahrain and its Gulf Arab allies are said to be making progress on an aid program to help the island-kingdom repair its finances and avoid a devaluation that could roil neighboring markets.
Officials from Bahrain, Saudi Arabia, the United Arab Emirates and Kuwait are discussing a multi-year program that would involve spending cuts and measures to increase non-oil revenue, including the introduction of a value-added tax, according to five people with knowledge of the matter. They asked not to be identified because the details aren’t public.
Best High Tech Stocks For 2019: Starbucks Corporation(SBUX)
Advisors’ Opinion:
- [By Paul Ausick]
Starbucks Corp. (NYSE: SBUX) fell about 1.1% Tuesday to post a new 52-week low of $50.11. Shares closed at $50.66 on Monday. The 52-week high is $61.94. Volume of around 10 million was about 3% higher than the daily average. The company had no specific news but a rival chain is stepping in to open new stores.
- [By Billy Duberstein]
After stagnating over the course of two and half years, Starbucks (NASDAQ:SBUX) stock is showing signs of perking up. In fact, since its summer swoon, better-than-expected earnings have catapulted shares a handsome 40% off their July 2018 lows.
- [By Douglas A. McIntyre]
Starbucks Corp. (NASDAQ: SBUX) has a new benefit for employees: child and adult care support. With a company called Care.com, it will start a new program. And the prices to Starbucks employees will be very low.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Starbucks (SBUX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Daniel B. Kline]
Visit nearly any Starbucks (NASDAQ:SBUX) at almost any time of day, and you’ll see proof that the company has succeeded in its goal of becoming a “third place” — a social center beyond the home or the workplace. Its tables may be occupied by people working on novels, groups of friends chatting, businesspeople conducting meetings, and maybe even couples on dates.
- [By Max Byerly]
Gabelli Funds LLC raised its holdings in Starbucks (NASDAQ:SBUX) by 33.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 433,317 shares of the coffee company’s stock after acquiring an additional 109,000 shares during the quarter. Gabelli Funds LLC’s holdings in Starbucks were worth $25,085,000 as of its most recent filing with the Securities and Exchange Commission.
Best High Tech Stocks For 2019: Aerohive Networks, Inc.(HIVE)
Advisors’ Opinion:
- [By Max Byerly]
Leidos (NYSE: LDOS) and Aerohive Networks (NYSE:HIVE) are both aerospace companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
- [By Stephan Byrd]
Here are some of the news articles that may have effected Accern’s rankings:
Get Anthera Pharmaceuticals alerts:
Cystic Fibrosis Drugs Market – Future Growth Prospects and Industry Trends Analyzed Till 2025 (digitaljournal.com) Analysts Anticipate Anthera Pharmaceuticals Inc (ANTH) Will Announce Earnings of -$0.60 Per Share (americanbankingnews.com) News Buzz : Blink Charging Co. (NASDAQ:BLNK), Genocea Biosciences, Inc. (NASDAQ:GNCA), Anthera … (journalfinance.net) Current Lumpy Stocks:: Jounce Therapeutics, Inc. (NASDAQ:JNCE), Aerohive Networks, Inc. (NYSE:HIVE), Anthera … (journalfinance.net) Porous, non-porous tantalum cups yielded similar septic, aseptic risks after revision THA (healio.com)
ANTH has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Tuesday, February 13th. Jefferies Financial Group reiterated a “hold” rating and set a $0.50 target price on shares of Anthera Pharmaceuticals in a research report on Thursday, March 15th. Roth Capital initiated coverage on Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They set a “buy” rating and a $10.00 target price on the stock. Finally, Piper Jaffray Companies downgraded Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a research report on Monday, March 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $3.44.
- [By Logan Wallace]
Aerohive Networks Inc (NYSE:HIVE) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 573,420 shares, a drop of 35.3% from the May 31st total of 885,671 shares. Based on an average trading volume of 381,201 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.8% of the shares of the stock are short sold.
- [By ]
Our Biggest Loser… And A Bunch Of Big Wins
Our biggest loser was back in January when we closed out of small communications equipment firm Aerohive Networks (Nasdaq: HIVE). On January 17, the company made a statement about its upcoming fourth-quarter earnings release, warning that revenue would likely be near the lower end of its guidance range. Investors didn’t take kindly to the news and sent shares tumbling by roughly 30%… well below our 15% trailing stop-loss. We ended up closing out with a 35% loss on the trade.
Best High Tech Stocks For 2019: Lexicon Pharmaceuticals, Inc.(LXRX)
Advisors’ Opinion:
- [By Joseph Griffin]
Aperio Group LLC increased its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 49.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 19,270 shares of the biopharmaceutical company’s stock after buying an additional 6,377 shares during the period. Aperio Group LLC’s holdings in Lexicon Pharmaceuticals were worth $165,000 as of its most recent SEC filing.
- [By Max Byerly]
Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Todd Campbell]
Sanofi’s also awaiting an FDA decision on sotagliflozin, a drug it licensed from Lexicon Pharmaceuticals (NASDAQ:LXRX) in 2015 for $300 million up front, up to $430 million in development and regulatory milestones, up to $990 million in specified sales milestones, and tiered, escalating royalties ranging from low double-digit percentages to 40% of net sales.
- [By Chris Lange]
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is making presentations at the American Diabetes Association on June 22 to 26. Lexicon recently traded at $13.58 a share, with a consensus analyst price target of $23.00 and a 52-week trading range of $7.67 to $18.00.
- [By Keith Speights]
Dividend Yield
Abbott Laboratories (NYSE:ABT) Drugs $109 billion 19.37 1.88%
AstraZeneca (NYSE: AZN) Drugs $93 billion 19.70 3.97%
Becton Dickinson and Co. (NYSE: BDX) Medical supplies $60 billion 17.74 1.29%
DexCom (NASDAQ: DXCM) Medical devices $8 billion N/A N/A
Eli Lilly and Co. (NYSE: LLY) Drugs $85 billion 14.91 2.77%
Insulet (NASDAQ: PODD) Medical devices $5 billion 273.03 N/A
Johnson & Johnson (NYSE: JNJ) Drugs, medical devices $325 billion 14.16 2.57%
Lexicon Pharmaceuticals (NASDAQ:LXRX) Drugs $1 billion N/A N/A
MannKind (NASDAQ: MNKD) Drugs $270 million N/A N/A
Medtronic (NYSE: MDT) Medical devices $117 billion 15.36 2.14%
Merck & Co. (NYSE: MRK) Drugs $159 billion 12.99 3.22%
Novo Nordisk (NYSE:NVO) Drugs $116 billion 18.29 2.61%
Pfizer (NYSE: PFE) Drugs $209 billion 11.62 3.82%
Regeneron Pharmaceuticals (NASDAQ: REGN) Drugs $32 billion 13.95 N/A
Sanofi (NYSE: SNY) Drugs $95 billion 10.75 4.64%
Senseonics Holdings (NYSEMKT: SENS) Medical devices $447 million N/A N/A
Tandem Diabetes Care (NASDAQ: TNDM) Medical devices $711 million N/A N/AData source: Yahoo! Finance. P/E = price-to-earnings ratio; N/A = not applicable. Data as of May 25, 2018.
Best High Tech Stocks For 2019: NeoGenomics, Inc.(NEO)
Advisors’ Opinion:
- [By Logan Wallace]
Get a free copy of the Zacks research report on NeoGenomics (NEO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
NEO (CURRENCY:NEO) traded up 3.5% against the dollar during the 1-day period ending at 16:00 PM Eastern on October 8th. NEO has a market capitalization of $1.21 billion and $161.27 million worth of NEO was traded on exchanges in the last day. One NEO coin can currently be purchased for approximately $18.64 or 0.00280368 BTC on major cryptocurrency exchanges including LBank, ZB.COM, Gate.io and Allcoin. In the last seven days, NEO has traded up 0.6% against the dollar.
- [By Joseph Griffin]
These are some of the media stories that may have effected Accern’s analysis:
Get NeoGenomics alerts:
NeoGenomics (NEO) Receives Buy Rating from Stephens (americanbankingnews.com) NeoGenomics Redeems 100% of Series A Redeemable Preferred Stock (finance.yahoo.com) Q2 2018 EPS Estimates for NeoGenomics, Inc. Cut by William Blair (NEO) (americanbankingnews.com) NeoGenomics (NEO) Receives Buy Rating from BTIG Research (americanbankingnews.com) Steven C. Jones Sells 2,000 Shares of NeoGenomics, Inc. (NEO) Stock (americanbankingnews.com)
NeoGenomics traded up $0.40, hitting $13.90, during trading on Tuesday, MarketBeat Ratings reports. 6,150 shares of the company’s stock traded hands, compared to its average volume of 498,468. NeoGenomics has a 52 week low of $7.08 and a 52 week high of $14.18. The company has a quick ratio of 1.85, a current ratio of 2.03 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $1.13 billion, a P/E ratio of 231.50, a price-to-earnings-growth ratio of 6.69 and a beta of 0.48.
- [By Ethan Ryder]
BidaskClub lowered shares of NeoGenomics (NASDAQ:NEO) from a strong-buy rating to a buy rating in a research note published on Wednesday.
Several other equities research analysts have also weighed in on the company. Leerink Swann began coverage on NeoGenomics in a report on Tuesday, August 21st. They issued an outperform rating and a $18.00 price objective for the company. Zacks Investment Research lowered NeoGenomics from a hold rating to a sell rating in a report on Thursday, July 19th. First Analysis set a $16.00 target price on NeoGenomics and gave the company a buy rating in a report on Tuesday, September 18th. BTIG Research reaffirmed a buy rating and set a $15.00 target price on shares of NeoGenomics in a report on Thursday, June 21st. Finally, Stephens reaffirmed a buy rating and set a $15.00 target price on shares of NeoGenomics in a report on Tuesday, June 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $19.25.
Best High Tech Stocks For 2019: Tesla Motors, Inc.(TSLA)
Advisors’ Opinion:
- [By John Rosevear]
This is an important deal. Tesla’s (NASDAQ:TSLA) Supercharger network has given it a big advantage in winning buyers away from internal-combustion alternatives. Any company looking to challenge Tesla will be at a disadvantage unless it can also provide its buyers with assurance that they’ll be able to access high-speed chargers on road trips.
- [By ]
The solution to this problem — that is, night — is to build huge batteries, something that so far has been a real challenge. Right now, Tesla (Nasdaq: TSLA) has the world’s largest battery, a 100-megawatt beauty in Australia, about the size of a U.S. football field. That makes for a lot o’ juice. Enough, in fact, to power 30,000 homes.
- [By John Rosevear]
General Motors (NYSE:GM) and Honda Motor (NYSE:HMC) announced that they plan to team up on advanced batteries for electric vehicles in a bid to push back against Tesla (NASDAQ:TSLA) and its massive Gigafactory.
- [By Rich Smith]
I dusted off my crystal ball earlier this year and made three (I thought not very) bold predictions about what investors could expect from Tesla (NASDAQ:TSLA) stock in 2018. As we approach the midpoint mark of the year, however, it looks like I’m batting only .333:
Best High Tech Stocks For 2019: OraSure Technologies, Inc.(OSUR)
Advisors’ Opinion:
- [By Shane Hupp]
Integra Lifesciences (NASDAQ: OSUR) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
- [By Shane Hupp]
Get a free copy of the Zacks research report on OraSure Technologies (OSUR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) have been given an average rating of “Buy” by the seven research firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $20.00.
- [By Max Byerly]
SurModics (NASDAQ: OSUR) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.